



































## Public Offerings

**2014:** Market leaders and major investment banks engaged in capital markets transactions throughout the United States and Europe turn to WilmerHale for legal advice and business advantage. In 2013, we handled more than 40 public offerings and Rule 144A placements raising approximately \$20 billion, for leading companies in life sciences, technology, financial services, communications and other industries. Since 2004, we have served as counsel in more than 400 public offerings and Rule 144A placements raising nearly \$150 billion. Over the past 15 years, our IPO practice—which ranks among the top in the United States—has handled more IPOs in the eastern United States, as both issuer counsel and underwriters' counsel, than any other law firm. The following is a selection of our recent capital markets transactions.

# Counsel of Choice for Public Offerings

SERVING INDUSTRY LEADERS IN TECHNOLOGY, LIFE SCIENCES, CLEANTECH, FINANCIAL SERVICES, COMMUNICATIONS AND BEYOND



 <b>ENDURANCE</b> <small>DRUGS AND BIOTECHNOLOGY</small> Initial Public Offering of Common Stock <b>\$252,612,000</b> Counsel to Issuer October 2013	 <b>Epizyme</b> Initial Public Offering of Common Stock <b>\$88,700,000</b> Counsel to Issuer June 2013	 <b>MERRIMACK</b> <small>PHARMACEUTICALS</small> Public Offering of Convertible Senior Notes <b>\$125,000,000</b> Counsel to Issuer July 2013	 <b>Yandex</b> Public Offering of Class A Ordinary Shares <b>\$606,956,000</b> Counsel to Issuer March 2013	 <b>AVEO</b> <small>ONCOLOGY</small> Public Offering of Common Stock <b>\$57,503,000</b> Counsel to Issuer January 2013	 <b>channeladvisor</b> Initial Public Offering of Common Stock <b>\$92,575,000</b> Counsel to Underwriters May 2013	 <b>DURATA</b> <small>THERAPEUTICS</small> Public Offering of Common Stock <b>\$57,558,000</b> Counsel to Issuer April 2013	 <b>agios</b> Initial Public Offering of Common Stock <b>\$121,900,000</b> Counsel to Issuer July 2013	
 <b>Karyopharm</b> <small>THERAPEUTICS</small> Initial Public Offering of Common Stock <b>\$125,120,000</b> Counsel to Issuer December 2013	 <b>WhiteWave</b> Public Offering of Common Stock <b>\$610,600,000</b> Counsel to Issuer July 2013	 <b>FSP</b> <small>FRANKLIN STREET PROPERTIES</small> Public Offering of Common Stock <b>\$241,500,000</b> Counsel to Issuer May 2013	 <b>wex</b> Rule 144A Placement of Senior Notes <b>\$400,000,000</b> Counsel to Issuer January 2013	 <b>uniQure</b> Initial Public Offering of Common Shares <b>\$91,800,000</b> Counsel to Issuer February 2014	 <b>PTC</b> <small>THERAPEUTICS</small> Initial Public Offering of Common Stock <b>\$144,417,000</b> Counsel to Issuer June 2013	 <b>MACROGENICS</b> Initial Public Offering of Common Stock <b>\$92,000,000</b> Counsel to Underwriters October 2013	 <b>ACHILLION</b> Public Offering of Common Stock <b>\$141,913,000</b> Counsel to Issuer February 2013	 <b>Sensata</b> <small>Technologies</small> Public Offerings of Ordinary Shares <b>\$1,540,250,000</b> Counsel to Underwriters February, May and December 2013
 <b>OPHTHOTECH</b> Initial Public Offering of Common Stock <b>\$192,280,000</b> Counsel to Issuer September 2013	 <b>PACIRA</b> <small>PHARMACEUTICALS, INC.</small> Rule 144A Placement of Convertible Senior Notes <b>\$120,000,000</b> Counsel to Issuer January 2013	 <b>demandware</b> Public Offering of Common Stock <b>\$216,977,000</b> Counsel to Issuer November 2013	 <b>Infinity</b> <small>PHARMACEUTICALS</small> Public Offering of Common Stock <b>\$456,663,000</b> Counsel to Issuer April 2013	 <b>Argos</b> <small>THERAPEUTICS</small> Initial Public Offering of Common Stock <b>\$45,000,000</b> Counsel to Issuer February 2014	 <b>The Medicines Company</b> Public Offering of Common Stock <b>\$201,250,000</b> Counsel to Issuer August 2013	 <b>CoNCERT</b> Initial Public Offering of Common Stock <b>\$84,000,000</b> Counsel to Issuer February 2014	 <b>ANALOG DEVICES</b> Public Offering of 2.875% Senior Notes <b>\$500,000,000</b> Counsel to Issuer June 2013	
 <b>TETRAPHASE</b> <small>PHARMACEUTICALS</small> Initial Public Offering of Common Stock <b>\$75,000,000</b> Counsel to Issuer March 2013	 <b>STATE STREET</b> Public Offerings of Senior Notes <b>\$2,500,000,000</b> Counsel to Issuer May and November 2013	 <b>STAPLES</b> Public Offering of Senior Notes <b>\$1,000,000,000</b> Counsel to Issuer January 2013	 <b>Discovery</b> <small>COMMUNICATIONS</small> Public Offering of Senior Notes <b>\$1,200,000,000</b> Counsel to Issuer March 2013	 <b>ELEVEN</b> <small>PHARMACEUTICALS</small> Initial Public Offering of Common Stock <b>\$50,000,000</b> Counsel to Issuer February 2014	 <b>ThermoFisher</b> <small>SCIENTIFIC</small> Public Offering of Senior Notes <b>\$3,200,000,000</b> Counsel to Issuer December 2013	 <b>SSiC</b> Public Offerings of Common Stock <b>\$724,089,000</b> Counsel to Issuer March, May and September 2013		



**Mixed Sources**  
Product group from well-managed  
forests, controlled sources and  
recycled wood or fiber  
www.fsc.org Cert no. BV-COC-070904  
© 1996 Forest Stewardship Council

14\_0040 UNI 2/14 3,000 *WilmerHale recognizes its corporate responsibility to environmental stewardship.*

[wilmerhale.com](http://wilmerhale.com)

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at [www.sra.org.uk/solicitors/code-of-conduct.page](http://www.sra.org.uk/solicitors/code-of-conduct.page). A list of partners and their professional qualifications is available for inspection at our UK offices. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2014 Wilmer Cutler Pickering Hale and Dorr LLP